OBJECTIVE: Charcot-Marie-Tooth disease covers a group of inherited peripheral neuropathies. The aim of this study was to investigate the effect of targeted next-generation sequencing panels on the ...

A look at the shareholders of Qiagen N.V. (NYSE:QGEN) can tell us which group is most powerful. The group holding the most number of shares in the company, around 82% to be precise, is institutions.

QIAGEN indicated it is considering additional measures to increase shareholder returns in 2026 and beyond. The company, which employs approximately 5,700 people across over 35 locations, provides ...

QIAGEN delivers well ahead of schedule on its commitment to return at least $1 billion through end-2028, considering additional ways to increase returns in 2026 and beyond VENLO, Netherlands, December ...

Parse Biosciences co-founders are CTO Charles Roco and CEO Alex Rosenberg. (Parse Photo) Seattle’s Parse Biosciences is teed up for an acquisition by Qiagen, a Netherlands-based holding company, in a ...

Qiagen Chief Executive Thierry Bernard plans to step down from the biotechnology provider. Bernard has been chief executive for six years and will resign after a successor is appointed, the ...

The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, it also revealed that its long-term chief executive, Thierry Bernard, will ...

Momentum building as QIAGEN prepares for three important new instrument launches in 2025 and 2026: QIAsymphony Connect, QIAsprint and QIAmini VENLO, Netherlands, & GERMANTOWN, Maryland--(BUSINESS WIRE ...

VENLO, Netherlands, & GERMANTOWN, Maryland--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the 4,000th placement of its QIAcube Connect instrument, a significant ...

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing QIAcube Connect drives lab efficiency by automating critical steps in molecular biology workflows ...

Momentum building as QIAGEN prepares for three important new instrument launches in 2025 and 2026: QIAsymphony Connect, QIAsprint and QIAmini VENLO, Netherlands ...